Neumora Therapeutics Announces Major Leadership Restructuring as Paul Berns Takes CEO Role
核心洞察
Neumora Therapeutics undergoes significant leadership changes with Paul L. Berns, co-founder and executive chair, assuming the role of CEO and chairman of the Board effective February 14, 2025.
The clinical-stage biopharmaceutical company is advancing seven neuroscience programs, with three clinical-stage programs expected to deliver data readouts in 2025, including Phase 3 results for navacaprant in depression (搜索).
Joshua Pinto, Ph.D., has been appointed as president, while Bill Aurora, Pharm.D., and Michael Milligan take on roles as chief operating and development officer and chief financial officer, respectively.
In a significant leadership transition, Neumora Therapeutics, Inc. (Nasdaq: NMRA) has announced that Paul L. Berns, the company's co-founder and executive chair of the Board of Directors, will assume the role of chief executive officer and chairman of the Board, effective February 14, 2025. The restructuring comes as current leader Henry Gosebruch departs the company.
Strategic Leadership Appointments
The leadership reorganization extends beyond the CEO position, with Joshua Pinto, Ph.D., stepping into the role of president, Bill Aurora, Pharm.D., taking the position of chief operating and development officer, and Michael Milligan assuming the role of chief financial officer.
"Neumora is poised to reach its potential, working to maximize shareholder value, and most importantly, to make a difference for the millions of people living with brain diseases," stated Paul L. Berns, emphasizing the company's commitment to its mission.
Robust Pipeline and Near-term Milestones
Neumora stands at the forefront of neuroscience drug development with seven novel programs in its pipeline, including several approaching critical milestones. The company anticipates four clinical data readouts in the immediate future, with particular attention focused on the ongoing Phase 3 program evaluating navacaprant for depression (搜索).
The company's innovative approach to brain disease treatment development is supported by an integrated suite of translational, clinical, and computational tools designed to enable precision medicine approaches. This technological foundation strengthens Neumora's position in addressing some of the most prevalent neurological conditions.
Financial Update and Future Outlook
The company has scheduled a conference call for March 3, 2025, where it will present its fourth quarter and full year 2024 financial results alongside a comprehensive business update. The presentation will provide stakeholders with detailed insights into the company's progress and strategic direction under its new leadership structure.
Dr. Joshua Pinto, speaking about his new role as president, expressed optimism about the company's trajectory: "Neumora is in a strong position, advancing studies in some of the most prevalent brain diseases with multiple near-term clinical inflection points. We have an industry leading pipeline and the opportunity to reshape how brain diseases are thought about and treated."